PCSK9 inhibitors. Recommendations for patient selection

被引：1

作者：

Laufs, U. ^{[1
]}

Custodis, F. ^{[1
]}

Werner, C. ^{[1
]}

机构：

[1] Univ Klinikum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, IMED Geb 41-1, D-66421 Homburg, Germany

来源：

HERZ | 2016年 / 41卷 / 04期

关键词：

Proprotein convertase subtilisin-kexin type 9; Safety; Cholesterol; Risk; Review; CORONARY-HEART-DISEASE; SUBTILISIN/KEXIN TYPE 9; DENSITY-LIPOPROTEIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODY; STATIN THERAPY; CARDIOVASCULAR EVENTS; LDL-CHOLESTEROL; REDUCING LIPIDS; AMG; 145;

D O I：

10.1007/s00059-016-4429-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The 2 or 4aEuroweek subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60 %. The therapy is well-tolerated. The safety profile in the published studies is comparable to placebo. Outcome data and information on long-term safety and the influence on cardiovascular events are not yet available but the results of several large trials are expected in 2016-2018. At present (spring 2016) PCSK9 inhibitors represent an option for selected patients with a high cardiovascular risk and high LDL-C despite treatment with the maximum tolerated oral lipid-lowering therapy. This group includes selected patients with familial hypercholesterolemia and high-risk individuals with statin-associated muscle symptoms (SAMS).

引用

页码：296 / 306

页数：11

共 43 条

[21] Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin [J].

Kuhnast, Susan ;

van der Hoorn, Jose W. A. ;

Pieterman, Elsbet J. ;

van den Hoek, Anita M. ;

Sasiela, William J. ;

Gusarova, Viktoria ;

Peyman, Anusch ;

Schaefer, Hans-Ludwig ;

Schwahn, Uwe ;

Jukema, J. Wouter ;

Princen, Hans M. G. .

JOURNAL OF LIPID RESEARCH, 2014, 55 (10) :2103-2112

[22] Treatment Options for Statin-Associated Muscle Symptoms [J].

Laufs, Ulrich ;

Scharnagl, Hubert ;

Halle, Martin ;

Windler, Eberhard ;

Endres, Matthias ;

Maerz, Winfried .

DEUTSCHES ARZTEBLATT INTERNATIONAL, 2015, 112 (44) :748-U21

[23] Simplified algorithm to facilitate communication of familial hypercholesterolaemia [J].

Laufs, Ulrich ;

Parhofer, Klaus G. .

EUROPEAN HEART JOURNAL, 2015, 36 (43) :3004-3006

[24] Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia [J].

Le May, Cedric ;

Kourimate, Sanae ;

Langhi, Cedric ;

Chetiveaux, Maud ;

Jarry, Anne ;

Comera, Christine ;

Collet, Xavier ;

Kuipers, Folkert ;

Krempf, Michel ;

Cariou, Bertrand ;

Costet, Philippe .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (05) :684-U157

[25] PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells [J].

Levy, Emile ;

Ouadda, Ali Ben Djoudi ;

Spahis, Schohraya ;

Sane, Alain Theophile ;

Garofalo, Carole ;

Grenier, Emilie ;

Emonnot, Lea ;

Yara, Sabrina ;

Couture, Patrick ;

Beaulieu, Jean-Francois ;

Menard, Daniel ;

Seidah, Nabil G. ;

Elchebly, Mounib .

ATHEROSCLEROSIS, 2013, 227 (02) :297-306

[26] A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia [J].

Marks, D ;

Thorogood, M ;

Neil, HAW ;

Humphries, SE .

ATHEROSCLEROSIS, 2003, 168 (01) :1-14

[27] Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice [J].

Maxwell, KN ;

Soccio, RE ;

Duncan, EM ;

Schayek, E ;

Breslow, JL .

JOURNAL OF LIPID RESEARCH, 2003, 44 (11) :2109-2119

[28] Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial [J].

Moriarty, Patrick M. ;

Jacobson, Terry A. ;

Bruckert, Eric ;

Thompson, Paul D. ;

Guyton, John R. ;

Baccara-Dinet, Marie T. ;

Gipe, Daniel .

JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (06) :554-561

[29] Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease [J].

Nordestgaard, Borge G. ;

Chapman, M. John ;

Humphries, Steve E. ;

Ginsberg, Henry N. ;

Masana, Luis ;

Descamps, Olivier S. ;

Wiklund, Olov ;

Hegele, Robert A. ;

Raal, Frederick J. ;

Defesche, Joep C. ;

Wiegman, Albert ;

Santos, Raul D. ;

Watts, Gerald F. ;

Parhofer, Klaus G. ;

Hovingh, G. Kees ;

Kovanen, Petri T. ;

Boileau, Catherine ;

Averna, Maurizio ;

Boren, Jan ;

Bruckert, Eric ;

Catapano, Alberico L. ;

Kuivenhoven, Jan Albert ;

Pajukanta, Paeivi ;

Ray, Kausik ;

Stalenhoef, Anton F. H. ;

Stroes, Erik ;

Taskinen, Marja-Riitta ;

Tybjaerg-Hansen, Anne .

EUROPEAN HEART JOURNAL, 2013, 34 (45) :3478-+

[30] Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver [J].

Park, SW ;

Moon, YA ;

Horton, JD .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (48) :50630-50638

← 1 2 3 4 5 →